207 related articles for article (PubMed ID: 35213654)
1. Hydrogen-producing small intestinal bacterial overgrowth is associated with hepatic encephalopathy and liver function.
Yokoyama K; Sakamaki A; Takahashi K; Naruse T; Sato C; Kawata Y; Tominaga K; Abe H; Sato H; Tsuchiya A; Kamimura K; Takamura M; Yokoyama J; Terai S
PLoS One; 2022; 17(2):e0264459. PubMed ID: 35213654
[TBL] [Abstract][Full Text] [Related]
2. [Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of Rifaximin].
Liu ZJ; Wei H; Duan LP; Zhu SW; Zhang L; Wang K
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1896-902. PubMed ID: 27373356
[TBL] [Abstract][Full Text] [Related]
3. Preferential usage of rifaximin for the treatment of hydrogen-positive smallintestinal bacterial overgrowth.
Barkin JA; Keihanian T; Barkin JS; Antequera CM; Moshiree B
Rev Gastroenterol Peru; 2019; 39(2):111-115. PubMed ID: 31333225
[TBL] [Abstract][Full Text] [Related]
4. Small Intestinal Bacterial Overgrowth Diagnosed by a Breath Test and Improved by Rifaximin in a Patient with Hepatic Encephalopathy and Alcoholic Liver Cirrhosis.
Sakamaki A; Yokoyama K; Yamazaki F; Kamimura H; Kamimura K; Takamura M; Yokoyama J; Terai S
Intern Med; 2020 Aug; 59(15):1849-1853. PubMed ID: 32321898
[TBL] [Abstract][Full Text] [Related]
5. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy.
Gupta A; Dhiman RK; Kumari S; Rana S; Agarwal R; Duseja A; Chawla Y
J Hepatol; 2010 Nov; 53(5):849-55. PubMed ID: 20675008
[TBL] [Abstract][Full Text] [Related]
6. Elevated methane levels in small intestinal bacterial overgrowth suggests delayed small bowel and colonic transit.
Suri J; Kataria R; Malik Z; Parkman HP; Schey R
Medicine (Baltimore); 2018 May; 97(21):e10554. PubMed ID: 29794732
[TBL] [Abstract][Full Text] [Related]
7. Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome.
Zhuang X; Tian Z; Luo M; Xiong L
BMC Gastroenterol; 2020 Jun; 20(1):187. PubMed ID: 32532214
[TBL] [Abstract][Full Text] [Related]
8. Association Between Small Intestinal Bacterial Overgrowth by Glucose Breath Test and Coronary Artery Disease.
Fialho A; Fialho A; Kochhar G; Schenone AL; Thota P; McCullough AJ; Shen B
Dig Dis Sci; 2018 Feb; 63(2):412-421. PubMed ID: 29110161
[TBL] [Abstract][Full Text] [Related]
9. Methane production and small intestinal bacterial overgrowth in children living in a slum.
Mello CS; Tahan S; Melli LC; Rodrigues MS; de Mello RM; Scaletsky IC; de Morais MB
World J Gastroenterol; 2012 Nov; 18(41):5932-9. PubMed ID: 23139610
[TBL] [Abstract][Full Text] [Related]
10. [Features of nutrition pattern of patients with small intestinal bacterial overgrowth resistant to therapy].
Pilipenko VI; Isakov VA; Vlasova AV; Naidenova MA
Vopr Pitan; 2019; 88(5):31-38. PubMed ID: 31710785
[TBL] [Abstract][Full Text] [Related]
11. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients.
Zhao J; Zheng X; Chu H; Zhao J; Cong Y; Fried M; Fox M; Dai N
Neurogastroenterol Motil; 2014 Jun; 26(6):794-802. PubMed ID: 24641100
[TBL] [Abstract][Full Text] [Related]
12. Small Intestinal Bacterial Overgrowth Is Associated with Non-Alcoholic Fatty Liver Disease.
Fialho A; Fialho A; Thota P; McCullough AJ; Shen B
J Gastrointestin Liver Dis; 2016 Jun; 25(2):159-65. PubMed ID: 27308646
[TBL] [Abstract][Full Text] [Related]
13. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial.
Lunia MK; Sharma BC; Sharma P; Sachdeva S; Srivastava S
Clin Gastroenterol Hepatol; 2014 Jun; 12(6):1003-8.e1. PubMed ID: 24246768
[TBL] [Abstract][Full Text] [Related]
14. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.
Majewski M; McCallum RW
Adv Med Sci; 2007; 52():139-42. PubMed ID: 18217406
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth.
Furnari M; Parodi A; Gemignani L; Giannini EG; Marenco S; Savarino E; Assandri L; Fazio V; Bonfanti D; Inferrera S; Savarino V
Aliment Pharmacol Ther; 2010 Oct; 32(8):1000-6. PubMed ID: 20937045
[TBL] [Abstract][Full Text] [Related]
16. Association between small-intestinal bacterial overgrowth and deep vein thrombosis in patients with spinal cord injuries.
Cheng X; Zhang L; Xie NC; Xu HL; Lian YJ
J Thromb Haemost; 2017 Feb; 15(2):304-311. PubMed ID: 27930853
[TBL] [Abstract][Full Text] [Related]
17. Minimal Hepatic Encephalopathy: Effect of H. pylori infection and small intestinal bacterial overgrowth treatment on clinical outcomes.
Abid S; Kamran M; Abid A; Butt N; Awan S; Abbas Z
Sci Rep; 2020 Jun; 10(1):10079. PubMed ID: 32572109
[TBL] [Abstract][Full Text] [Related]
18. Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis.
Zhang Y; Feng Y; Cao B; Tian Q
Int J Clin Exp Med; 2015; 8(2):2954-7. PubMed ID: 25932262
[TBL] [Abstract][Full Text] [Related]
19. Serum Gastrin Predicts Hydrogen-Producing Small Intestinal Bacterial Overgrowth in Patients With Abdominal Surgery: A Prospective Study.
Kim YJ; Paik CN; Jo IH; Kim DB; Lee JM
Clin Transl Gastroenterol; 2020 Dec; 12(1):e00291. PubMed ID: 33369565
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth.
Majewski M; Reddymasu SC; Sostarich S; Foran P; McCallum RW
Am J Med Sci; 2007 May; 333(5):266-70. PubMed ID: 17505166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
